Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × INDUSTRY × dolasetron × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1 Neoplasms 1 Nausea 1

Interventions

Zoledronic Acid 18 nilotinib 11 Docetaxel 11 Bevacizumab 11 Everolimus 10 Letrozole 9 Imatinib Mesylate 9 Erlotinib Hydrochloride 9 Drug Therapy 9 enzalutamide 8 Paclitaxel 8 Capecitabine 8 pegfilgrastim 7 icotinib 6 Trastuzumab 6 Rituximab 6 Prednisone 6 Oxycodone 6 Nivolumab 6 Imiquimod 6 Gemcitabine 6 Epoetin Alfa 6 Diclofenac 6 Cisplatin 6 Carboplatin 6 Anastrozole 6 exemestane 5 epoetin beta 5 Leuprolide 5 Gefitinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01636947 2018-09-25

KMEC

Merck Sharp & Dohme LLC

Phase 4 Completed

494 enrolled 14 charts

Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon ⚡